222 related articles for article (PubMed ID: 27244239)
21. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells.
Barbetti V; Gozzini A; Rovida E; Morandi A; Spinelli E; Fossati G; Mascagni P; Lübbert M; Dello Sbarba P; Santini V
Oncogene; 2008 Mar; 27(12):1767-78. PubMed ID: 17891169
[TBL] [Abstract][Full Text] [Related]
22. Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes.
Pattabiraman DR; McGirr C; Shakhbazov K; Barbier V; Krishnan K; Mukhopadhyay P; Hawthorne P; Trezise A; Ding J; Grimmond SM; Papathanasiou P; Alexander WS; Perkins AC; Levesque JP; Winkler IG; Gonda TJ
Blood; 2014 Apr; 123(17):2682-90. PubMed ID: 24596419
[TBL] [Abstract][Full Text] [Related]
23. E2A proteins enhance the histone acetyltransferase activity of the transcriptional co-activators CBP and p300.
Hyndman BD; Thompson P; Bayly R; Côté GP; LeBrun DP
Biochim Biophys Acta; 2012 May; 1819(5):446-53. PubMed ID: 22387215
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of lysine acetyltransferase KAT3B/p300 activity by a naturally occurring hydroxynaphthoquinone, plumbagin.
Ravindra KC; Selvi BR; Arif M; Reddy BA; Thanuja GR; Agrawal S; Pradhan SK; Nagashayana N; Dasgupta D; Kundu TK
J Biol Chem; 2009 Sep; 284(36):24453-64. PubMed ID: 19570987
[TBL] [Abstract][Full Text] [Related]
25. The RUNX1/RUNX1T1 network: translating insights into therapeutic options.
Swart LE; Heidenreich O
Exp Hematol; 2021 Feb; 94():1-10. PubMed ID: 33217477
[TBL] [Abstract][Full Text] [Related]
26. Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia.
Wu T; Hu J; Zhao X; Zhang C; Dong R; Hu Q; Xu H; Shen H; Zhang X; Zhang Y; Lin B; Wu X; Xiang Q; Xu Y
J Med Chem; 2024 Jun; 67(11):9194-9213. PubMed ID: 38829718
[TBL] [Abstract][Full Text] [Related]
27. Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerization.
Schanda J; Lee CW; Wohlan K; Müller-Kuller U; Kunkel H; Coco IQ; Stein S; Metz A; Koch J; Lausen J; Platzbecker U; Medyouf H; Gohlke H; Heuser M; Eder M; Grez M; Scherr M; Wichmann C
Haematologica; 2017 May; 102(5):e170-e174. PubMed ID: 28154087
[No Abstract] [Full Text] [Related]
28. Histone acetyltransferase p300 is induced by p38MAPK after photodynamic therapy: the therapeutic response is increased by the p300HAT inhibitor anacardic acid.
Tsai YJ; Tsai T; Peng PC; Li PT; Chen CT
Free Radic Biol Med; 2015 Sep; 86():118-32. PubMed ID: 26001729
[TBL] [Abstract][Full Text] [Related]
29. Roles of HIPK1 and HIPK2 in AML1- and p300-dependent transcription, hematopoiesis and blood vessel formation.
Aikawa Y; Nguyen LA; Isono K; Takakura N; Tagata Y; Schmitz ML; Koseki H; Kitabayashi I
EMBO J; 2006 Sep; 25(17):3955-65. PubMed ID: 16917507
[TBL] [Abstract][Full Text] [Related]
30. A novel cell-permeable, selective, and noncompetitive inhibitor of KAT3 histone acetyltransferases from a combined molecular pruning/classical isosterism approach.
Milite C; Feoli A; Sasaki K; La Pietra V; Balzano AL; Marinelli L; Mai A; Novellino E; Castellano S; Tosco A; Sbardella G
J Med Chem; 2015 Mar; 58(6):2779-98. PubMed ID: 25730130
[TBL] [Abstract][Full Text] [Related]
31. Structural determinants of the catalytic inhibition of human topoisomerase IIα by salicylate analogs and salicylate-based drugs.
Bau JT; Kurz EU
Biochem Pharmacol; 2014 Jun; 89(4):464-76. PubMed ID: 24695359
[TBL] [Abstract][Full Text] [Related]
32. GFI1 is required for
Marneth AE; Botezatu L; Hönes JM; Israël JCL; Schütte J; Vassen L; Lams RF; Bergevoet SM; Groothuis L; Mandoli A; Martens JHA; Huls G; Jansen JH; Dührsen U; Berg T; Möröy T; Wichmann C; Lo MC; Zhang DE; van der Reijden BA; Khandanpour C
Haematologica; 2018 Sep; 103(9):e395-e399. PubMed ID: 29674496
[No Abstract] [Full Text] [Related]
33. Epigenetic Silencing of Eyes Absent 4 Gene by Acute Myeloid Leukemia 1-Eight-twenty-one Oncoprotein Contributes to Leukemogenesis in t(8;21) Acute Myeloid Leukemia.
Huang S; Jiang MM; Chen GF; Qian K; Gao HH; Guan W; Shi JL; Liu AQ; Liu J; Wang BH; Li YH; Yu L
Chin Med J (Engl); 2016 Jun; 129(11):1355-62. PubMed ID: 27231175
[TBL] [Abstract][Full Text] [Related]
34. AML1/RUNX1 functions as a cytoplasmic attenuator of NF-κB signaling in the repression of myeloid tumors.
Nakagawa M; Shimabe M; Watanabe-Okochi N; Arai S; Yoshimi A; Shinohara A; Nishimoto N; Kataoka K; Sato T; Kumano K; Nannya Y; Ichikawa M; Imai Y; Kurokawa M
Blood; 2011 Dec; 118(25):6626-37. PubMed ID: 22021368
[TBL] [Abstract][Full Text] [Related]
35. Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells.
Trombly DJ; Whitfield TW; Padmanabhan S; Gordon JA; Lian JB; van Wijnen AJ; Zaidi SK; Stein JL; Stein GS
BMC Genomics; 2015 Apr; 16(1):309. PubMed ID: 25928846
[TBL] [Abstract][Full Text] [Related]
36. Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong
Hu J; Xu H; Wu T; Zhang C; Shen H; Dong R; Hu Q; Xiang Q; Chai S; Luo G; Chen X; Huang Y; Zhao X; Peng C; Wu X; Lin B; Zhang Y; Xu Y
J Med Chem; 2024 May; 67(9):6952-6986. PubMed ID: 38649304
[TBL] [Abstract][Full Text] [Related]
37. Acetylation dependent functions of Rab22a-NeoF1 Fusion Protein in Osteosarcoma.
Liang X; Wang X; He Y; Wu Y; Zhong L; Liu W; Liao D; Kang T
Theranostics; 2020; 10(17):7747-7757. PubMed ID: 32685017
[No Abstract] [Full Text] [Related]
38. AML1-ETO targets and suppresses cathepsin G, a serine protease, which is able to degrade AML1-ETO in t(8;21) acute myeloid leukemia.
Jin W; Wu K; Li YZ; Yang WT; Zou B; Zhang F; Zhang J; Wang KK
Oncogene; 2013 Apr; 32(15):1978-87. PubMed ID: 22641217
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors.
Liu R; Zhang Z; Yang H; Zhou K; Geng M; Zhou W; Zhang M; Huang X; Li Y
Eur J Med Chem; 2019 Oct; 180():171-190. PubMed ID: 31306905
[TBL] [Abstract][Full Text] [Related]
40. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia.
Ferrara FF; Fazi F; Bianchini A; Padula F; Gelmetti V; Minucci S; Mancini M; Pelicci PG; Lo Coco F; Nervi C
Cancer Res; 2001 Jan; 61(1):2-7. PubMed ID: 11196162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
